J

Johnson & Johnson

Makes prescription drugs and medical devices

Senior Oncology Sales Specialist - Solid Tumor, GU

Full-TimeUpdated on 10/23/2026Deadline 10/28/26
$98k - $178.3k+ Long-term incentive program
Junior
Bachelor's
Montana, USA+4 moreMore locations: Boise, ID, USA | Spokane, WA, USA | Billings, MT, USA | Idaho, USA
In PersonField-based territory role; travel as necessary, including overnight and/or weekend travel.
Sales & Account ManagementField Sales

About the job

Requirements
  • A minimum of a Bachelor's degree is required.
  • Oncology specialty sales experience and/or major hospital account sales experience is required.
  • A valid driver's license and ability to travel as necessary, including overnight and/or weekend travel, are required.
  • A minimum of two years of direct selling experience in pharmaceutical or biologic/biotech with documented success delivering sales results and achieving targets, or relevant clinical experience, is required.
  • Experience in hospital and large account sales, understanding complex reimbursement and managed care dynamics, and a documented history of successful sales performance in a competitive environment are required.
  • Strong relationship-building skills and the ability to identify key decision-makers are required.
  • Strong achievement motivation to meet and exceed goals is required.
  • Candidates must reside in the geography or be willing to relocate to it.
  • Ability to effectively use virtual technology and a history of engaging customers in virtual face-to-face interactions are required.
  • Preferred Skills lists Business Behavior, Clinical Experience, Coaching, Competitive Landscape Analysis, Cross-Functional Collaboration, Cultural Competence, Customer Centricity, Data Savvy, Developing Partnerships, Hematology, Market Knowledge, Oncology, Pharmaceutical Industry, Pharmaceutical Sales Marketing, Problem Solving, Product Knowledge, Sales, Sales Enablement, Sales Trend Analysis, and Strategic Sales Planning as skills.
Responsibilities
  • Fulfill sales strategies by selling current and potential new oncology therapeutics.
  • Demonstrate working knowledge of product clinical efficacy, provide clinical support or information as needed, and achieve the sales quota.
  • Conduct business analysis, actively prospect for new business within the assigned territory, and develop account strategies with the District Manager to increase territory sales, including identifying key accounts and health care professionals and developing specific penetration plans.
  • Develop customer-specific pre-call and post-call plans that include objectives, probes, and supporting materials.
  • Build customer dedication, identify and cultivate new relationships, influence decision-makers with targeted sales messages based on accurate clinical information, use approved sales and marketing materials, and execute local marketing strategies.
  • Use resources appropriately and collaborate with Johnson & Johnson Innovative Medicine team members and counterparts to share ideas and information and enhance business results.
  • Maintain strong knowledge of assigned specialty products and related markets in areas relevant to internal and external customers, including clinical, technical, and health economics.
  • Develop a complete understanding of the health care delivery system within each assigned account, including physician hierarchy, key pharmacy personnel, and clinical nursing staff.
  • Maintain knowledge of reimbursement, short- and long-term sales potential relative to the percentage of patients treated, patient mix, managed care organizations, specialty pharmacies, and new protocols or treatment modalities that affect business potential.
  • Attend and participate in required sales meetings, complete required training curriculum on time, achieve training standards, and efficiently complete administrative responsibilities, including health care compliance, expense reporting, call reporting, and other assignments.
Desired Qualifications
  • Solid Tumor, Urology, and/or rare disease specialty sales experience and an understanding of the Oncology market are preferred.
  • Previous product launch experience in a highly competitive environment is preferred.
  • Aptitude for learning AI and technology, demonstrated by commitment to exploring and iterating with emerging technologies and applying new tools over time, is preferred.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.